Multiple thrombophilic gene mutations rather than specific gene mutations are risk factors for recurrent miscarriage

American Journal of Reproductive Immunology

Volumn 55, Issue 5, 2006, Pages 360-368

  Coulam, Carolyn B ^a,b,d   Jeyendran, Rajasinqam S ^c   Fishel, Laurence A ^c   Roussev, Roumen ^b  

^a Rinehart Center for Reproductive Medicine   (United States)

^b Millenova Immunology Laboratories   (United States)

^c Andrology Laboratory Services   (United States)

^d NONE   (United States)

Author keywords

Inherited thrombophilia; Recurrent pregnancy loss; Thrombophilic genes

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8; DNA; FIBRINOGEN; PHOSPHOLIPID ANTIBODY; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN; THROMBOCYTE ANTIGEN;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA DETERMINATION; EXPERIENCE; FEMALE; FEMALE FERTILITY; GENE MUTATION; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; INHERITANCE; MAJOR CLINICAL STUDY; ORAL BIOPSY; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; RECURRENT ABORTION; RISK FACTOR; THROMBOPHILIA;

ABORTION, HABITUAL; ADULT; ANTIBODIES, ANTIPHOSPHOLIPID; BLOOD COAGULATION FACTORS; CASE-CONTROL STUDIES; FACTOR V; FEMALE; HEMOSTASIS; HETEROZYGOTE; HOMOZYGOTE; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MUTATION; PREGNANCY; PROTHROMBIN; RISK FACTORS; THROMBOPHILIA;

EID: 33645056805     PISSN: 10467408     EISSN: 16000897     Source Type: Journal    
DOI: 10.1111/j.1600-0897.2006.00376.x     Document Type: Article

References (66)

1. Brenner B, Sarig G, Weiner Z, Younis J, Blumenfeld Z, Lanir N: Thrombophilic polymorphisms are common in women with fetal loss without apparent cause. Thromb Haemost 1999; 82: 6-9.
2. Ridker PM, Miletich JP, Buring JE, Ariyo AA, Price DT, Manson JE, Hill JA: Factor V Leiden mutation as a risk factor for recurrent pregnancy loss. Ann Intern Med 1998; 128: 1000-1003.
3. Younis JS, Brenner B, Ohel G, Tal J, Lanir N, Ben-Ami M: Activated protein C resistance and factor V Leiden mutation can be associated with first-as well as second-trimester recurrent pregnancy loss. Am J Reprod Immunol 2000; 43: 31-35.
4. Sarig G, Younis JS, Hoffman R, Lanir N, Blumenfeld Z, Brenner B: Thrombophilia is common in women with idiopathic pregnancy loss and is associated with late pregnancy wastage. Fertil Steril 2002; 77: 342-347.
5. Finan RR, Tamim H, Ameen G, Sharida HE, Rashid M, Almawi WY: Prevalence of factor V G1691A (factor V-Leiden) and prothrombin G20210A gene mutations in a recurrent miscarriage population. Am J Hematol 2002; 71: 300-305.
6. Foka ZJ, Lambropoulos AF, Saravelos H, Karas GB, Karavida A, Agorastos T, Zournatzi V, Makris PE, Bontis J, Kotsis A: Factor V Leiden and prothrombin G20210A mutations, but not methylenetetrahydrofolate reductase C677T, are associated with recurrent miscarriages. Hum Reprod 2000; 15: 458-462.
7. Reznikoff-Etievan MF, Cayol V, Carbonne B, Robert A, Coulet F, Milliez J: Factor V Leiden and G20210A prothrombin mutations are risk factors for very early recurrent miscarriage. BJOG 2001; 108: 1251-1254.
8. Kovalevsky G, Gracia CR, Berlin JA, Sammel MD, Barnhart KT: Evaluation of the association between hereditary thrombophilia and recurrent pregnancy loss: A meta-analysis. Arch Intern Med 2004; 164: 558-563.
9. Pihusch R, Buchholz T, Lohse P, Rubsamen H, Rogenhofer N, Hasbargen U, Hiller E, Thaler CJ: Thrombophilic gene mutations and recurrent spontaneous abortion: Prothrombin mutation increases the risk in the first trimester. Am J Reprod Immunol 2001; 46: 124-131.
10. Wramsby ML, Sten-Linder M, Bremme K: Primary habitual abortions are associated with high frequency of factor V Leiden mutation. Fertil Steril 2000; 74: 987-991.
11. Rey E, Kahn SR, David M, Shrier I: Thrombophilic disorders and fetal loss: A meta-analysis. Lancet 2003; 361: 901-908.
12. Kutteh WH: Antiphospholipid antibody-associated recurrent pregnancy loss: Treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996; 174: 1584-1589.
13. Rai R, Cohen H, Dave M, Regan L: Randomized controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 1997; 314: 253-257.
14. Rai R, Shlebak A, Cohen H, Backos M, Holmes Z, Marroitt K, Regan L: Factor V Leiden and acquired activated protein C resistance among 1000 women with recurrent miscarriage. Hum Reprod 2001; 16: 961-965.
15. Grandone E, Margaglione M, Colaizzo D, d'Addedda M, Cappucci G, Vecchione G, Scianname N, Pavone G, Di Minno G: Factor V Leiden is associated with repeated and recurrent unexplained fetal losses. Thromb Haemost 1997; 77: 822-824.
16. Kornberg A, Raziel A, Rahimini-Levene N, Yona R, Sela BA, Ron-El R: Hypercoagulability and recurrent abortions. Blood 1998; 92 (Suppl. 1): 121b.
17. Nelen WL, Blom HJ, Thomas CM, Steegers EA, Boers CH, Eskes TK: Methylenetetrahydrofolate reductase polymorphism affects the change in homocysteine and folate concentrations resulting from low dose folic acid supplementation in women with unexplained recurrent miscarriages. J Nutr 1998; 128: 1336-1341.
18. Alonso A, Soto I, Urgelles MF, Corte JR, Rodriguez MJ, Pinto CR: Acquired and inherited thrombophilia in women with unexplained fetal losses. Am J Obstet Gynecol 2002; 187: 1337-1342.
19. Kutteh WH, Park VM, Deitcher SR: Hypercoagulable state mutation analysis in white patients with early first-trimester recurrent pregnancy loss. Fertil Steril 1999; 71: 1048-1053.
20. Dizon-Townson DS, Kinney S, Branch DW, Ward K: The factor V Leiden mutation is not a common cause of recurrent miscarriage. J Reprod Immunol 1997; 34: 217-223.
21. Souza SS, Ferriani RA, Pontes AG, Zago MA, Franco RF: Factor V Leiden and factor II G20210A mutations in patients with recurrent abortion. Hum Reprod 1999; 14: 2448-2450.
22. Pickering W, Marriott K, Regan L: G20210A prothrombin gene mutation: prevalence in a recurrent miscarriage population. Clin Appl Thromb Hemost 2001; 7: 25-28.
23. Deitcher SR, Park VM, Kutteh WH: Prothrombin 20210 G A mutation analysis in Caucasian women with early first trimester recurrent pregnancy loss. Blood 1998; 92 (Suppl. 1): 118b.
24. Deitcher SR, Park VM, Kutteh WH: Methylene tetrahydrofolate reductase 677CT mutation analysis in Caucasian women with early first trimester recurrent pregnancy loss. Blood 1998; 92 (Suppl. 1): 117b.
25. Dekker GA, de Vries JIP, Doelitzsch PM, Huijgens PC, Blomberg von BME, Jakobs C, Geijn van HP: Underlying disorders associated with severe early-onset preeclampsia. Am J Obstet Gynecol 1995; 173: 1042-1048.
26. Kupferminc MJ, Eldor A, Steinman N, Many A, Bar-Am A, Jaffa A, Fait G, Lessing JB: Increased frequency of the genetic thrombophilia in women with complications of pregnancy. N Eng J Med 1999; 340: 9-13.
27. Kupferminc MJ, Peri H, Zwang E, Yaron Y, Wolman I, Eldor A: High prevalence of the prothrombin gene mutation in women with intrauterine growth retardation, abruptio placentae and 2nd trimester loss. Acta Obstet Gynecol Scand 2000; 79: 963-967.
28. Morrison ER, Miedzybrodzka ZH, Campbell DM, Haites NE, Wilson BJ, Watson MS, Greaves M, Vickers MA: Prothrombotic genotypes are not associated with pre-eclampsia and gestational hypertension: Results from a large population-based study and systematic review. Thromb Haemost 2002; 87: 779-785.
29. Grandone E, Margaglione M, Colaizzo D, Pavone G, Paladini D, Martinelli P, Di Minni G: Low birth-weight in neonates of mothers carrying factor V G1691A and factor A 20210 mutations. Haematologica 2002; 87: 177-181.
30. Reznik R: Intrauterine growth restriction. Obstet Gynecol 2002; 99: 490-496.
31. van der Molen EF, Verbruggen B, Novakova I, Eskes TK, Monnens LA, Blom HJ: Hyperhomocysteinemia and other thrombotic risk factors in women with placental vasculopathy. BJOG 2000; 107: 785-791.
32. Tranquilli AL, Giannubilo SR, Dell'uomo B, Grandone E: Adverse pregnancy outcomes are associated with multiple maternal thrombophilic factors. Eur J Obstet Gynecol Reprod Biol 2004; 117: 144-147.
33. Castoldi E, Simioni P, Kalafatis M, Lunghi B, Tormene D, Girelli D, Girolami A, Bernardi F: Combinations of 4 mutations (FV R506Q, FV H1299R, FV Y1702C, PT 20210G/A) affecting the prothrombinase complex in a thrombophilic family. Blood 2000; 96: 1443-1448.
34. Buchholz T, Thaler IJ: Inherited thrombophilia: impact on human reproduction. Am J Reprod Immunol 2003; 50: 20-32.
35. Ozcan T, Rinder HM, Murphy J, Kohn C, Copel JA: Genetic thrombophilia and thromboembolic complications. Am J Obstet Gynecol 2001; 184: S189.
36. Kohler HP, Futers TS, Grant PJ: Prevalence of three common polymorphisms in the A-subunit gene of factor XIII in patients with coronary artery disease. Association with FXIII activity and antigen levels. Thromb Haemost 1999; 81: 511-515.
37. Kakko S, Elo T, Tapanainen JM, Huikuri HV, Savolainen MJ: Polymorphisms of genes affecting thrombosis and risk of myocardial infarction. Eur J Clin Invest 2002; 32: 643-648.
38. Pasrinen T, Perola M, Niini P, Terwilliger J, Salomaa V, Varriainen E, Peltone L, Syvanen AC: Array-based multiplex analysis of candidate genes reveals two independent and additive genetic risk factors for myocardial infarction in the Finnish population. Hum Mol Genet 1998; 7: 1453-1462.
39. Behague I, Poirier O, Nicaud V, Evans A, Arveiler D, Lue G et al: Beta fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction. The ECTIM study. Etude Cas-Temoins sur l'Infarctus du Myocarde. Circulation 1996; 93: 440-449.
40. Eriksson P, Kallin B, van Hooft FM, Bavenholm P, Hamsten A: Allele-specific increase in basal transcription of the plasminogen-activator 1 gene is associated with myocardial infarction. PNAS 1995; 92: 1851-1855.
41. Sartori MT, Wiman B, Vettore S, Dazzi F, Girolami A, Patrassi GM: 4G/5G polymorphism of PAI-1 gene promoter and fibrinolytic capacity in patients with deep vein thrombosis. Thromb Haemost 1998; 80: 956-960.
42. Gluek CJ, Phillips H, Cameron D, Wang P, Fontaine RN, Moore SK et al: The 4G/5G of the hypofibrinolytic plasminogen activator inhibitor type 1 gene: An independent risk factor for serious pregnancy complications. Metabolism 2000; 49: 845-852.
43. Feng DL, Lindpaintner K, Larson MG, Rao VS, O'Donnell CJ, Lipinska I, Schmitz C, Sutherland PA, Silbershatz H, D'Agostino RB, Muller JE, Meyers RH, Levy D, Tofler GH: Increased platelet aggregability associated with platelet GPIIIaP1 A2 polymorphism. The Framingham Offspring Study. Arterioscler Thromb Vasc Biol 1999; 19: 1142-1147.
44. Bojesen SE, Juul K, Schnohr P, Tybjaerg-Hansen A, Nordestgaard BG: Platelet glycoprotein IIb/IIIa homozygosity associated with risk of ischemic cardiovascular diseases and myocardial infarction in young men: the Copenhagen City Heart Study. J Am Coll Cardiol 2003; 42: 661-667.
45. Weisberg I, Tran P, Christensen B, Sibani S, Rozen R: A second genetic polymorphism in methlenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 1998; 64: 169-172.
46. Preston FE, Rosendaal FR, Walker ID, Bruet E, Berntorp E, Conrad J et al: Increased fetal loss in women with heritable thrombophilia. Lancet 1996; 348: 913-916.
47. Regan L, Rai R: Thrombophilia and pregnancy loss. J Reprod Immunol 2002; 55: 163-180.
48. Greer IA: The challenge of thrombophilia in maternal-fetal medicine. N Engl J Med 2000; 342: 424-425.
49. Hiller E, Pihusch R: Thrombophilia caused by congenital disorders of blood coagulation. Semin Thromb Hemost 1998; 116: 26-32.
50. Dahlenback B, Carlsson M, Svensson PJ: Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of cofactor to protein C. Proc Nat Acad Sci U S A 1993; 90: 1004-1008.
51. Brenner B, Vulfsons SL, Lanir N, Nahir M: Coexistinence of familial antiphospholipid syndrome and factor V Leiden: Impact on thrombotic diathesis. Br J Haematol 1996; 94: 166-167.
52. Younis JS, Brenner B, Obel G, Tal J, Lanir N, Ben Ami M: Activated protein C resistance and factor V Leiden mutation can be associated with first as well as second trimester recurrent pregnancy loss. Am J Reprod Immunol 2000; 40: 31-35.
53. Bare SN, Poka R, Balogh I, Ajzner E: Factor V Leiden as a risk factor for miscarriage and reduced fertility. Aust N Z J Obstet Gynaecol 2000; 40: 186-190.
54. Warburton D, Fraser FC: SpontDneous abortion risks in man: data from reproductive histories collected in a medical genetics unit. Am J Hum Genet 1964; 16: 1-25.
55. Kluijtmans LA, van den Heuvel LP, Boers GH, Frost P, Stevens EM, van Oost BA et al: Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet 1996; 55: 35-41.
56. Blumenfeld Z, Brenner B: Thrombophilia associated pregnancy wastage. Fertil Steril 1999; 72: 765-774.
57. Coumans AB, Huijgens PC, Jakobs C, Schats R, de Vries JI. Van Pampus MG et al: Haemostatic and metabolic abnormalities in women with unexplained recurrent abortion. Hum Reprod 1999; 14: 211-214.
58. Ogunyemi D, Cuellar F, Ku W, Arkel Y: Association between inherited thrombophilias, antiphophospholipid andtibodies and lipoprotein A levels and venous thromboembolism in pregnancy. Am J Perinatol 2003; 20: 17-24.
59. Brouwer JL, Bijl M, Veeger NJ, Kluin-Nelemans HC, van der Meer J: The contribution if inherited and acquired thrombophilic defects, alone or combined with antiphospholipid antibodies to venous and arterial thromboembolism in patients with systemic lupus erythematosus. Blood 2004; 104: 143-148.
60. Egbring R, Kroniger A, Seitz R: Factor XIII deficiency; pathologic mechanisms and clinical significance. Semin Thromb Hemost 1996; 22: 419-425.
61. Miloszewski K, Losowsky M: Fibrin stabilisation and factor XIII deficiency. In Fibrinogen, Fibrin Stabilisation and Fibrinolysis, L Francis (ed.). Horwood Publishing Limited, West Sussex, 1988, pp 175.
62. Gris JC, Ripart-Neveu S, Maugard C, Tailland ML, Brun S, Courtieu C et al: Respective evaluation of the prevalence of haemostasis abnormalities in unexplained primary early recurrent miscarriages. The Nimes Obstetricians Haematologists (NOHA) study. Thromb Haemost 1997; 77: 1096-1103.
63. Dekker GA, Sibai BM: Etiology and pathophysiology of preeclampsia current concepts. AJOG Review. Am J Obstet Gynecol 1998; 179: 1359-1375.
64. Many A, Schrieber L Rosner S, Lessing JB, Eldor A. Kupferminc MJ: Pathologic features of the placenta in women with severe pregnancy complications and thrombophilia. Obstet Gynecol 2001; 98: 1041-1044.
65. Aflalo ED, Sod-Moriah UA, Potashnik G, Har-Vardi I: Differences in the implantation rates of rat embryos developed in vivo and in vitro: possible role for plasminogen activators. Fertil Steril 2004; 81: 780-785.
66. Grandone E, Brancaccio V, Colaizzo D, Scianname N, Pavone G, Di Minno G, Margaglione M: Preventing adverse obstetric outcomes in women with genetic thrombophilia. Fertil Steril 2002; 78: 371-375.